Christian Reich
Overview
Explore the profile of Christian Reich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
2393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villa C, Biondich P, Draper N, Dores G, Storch E, Chada K, et al.
Transfusion
. 2024 Dec;
65(2):267-276.
PMID: 39709615
Background: U.S. FDA's Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative leverages large electronic health records and administrative claims data to conduct active surveillance for...
2.
Obidi J, Sridhar G, Dores G, Whitaker B, Villa C, Storch E, et al.
Transfusion
. 2024 May;
64(6):998-1007.
PMID: 38689458
Background: Current hemovigilance methods generally rely on survey data or administrative claims data utilizing billing and revenue codes, each of which has limitations. We used electronic health records (EHR) linked...
3.
Hu M, Shoaibi A, Feng Y, Lloyd P, Wong H, Smith E, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e248192.
PMID: 38656578
Importance: Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
4.
Tsafnat G, Dunscombe R, Gabriel D, Grieve G, Reich C
J Med Internet Res
. 2024 Apr;
26:e55779.
PMID: 38593431
Practitioners of digital health are familiar with disjointed data environments that often inhibit effective communication among different elements of the ecosystem. This fragmentation leads in turn to issues such as...
5.
Rajwa P, Borkowetz A, Abbott T, Alberti A, Bjartell A, Brash J, et al.
Eur Urol Open Sci
. 2024 Apr;
63:81-88.
PMID: 38572301
Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to androgen deprivation therapy, have been a game changer in...
6.
Lloyd P, Lufkin B, Moll K, Ogilvie R, McMahill-Walraven C, Beachler D, et al.
Vaccine
. 2024 Feb;
42(8):2004-2010.
PMID: 38388240
Background: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.)...
7.
Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, et al.
J Am Med Inform Assoc
. 2024 Jan;
31(3):583-590.
PMID: 38175665
Importance: The Observational Health Data Sciences and Informatics (OHDSI) is the largest distributed data network in the world encompassing more than 331 data sources with 2.1 billion patient records across...
8.
Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, et al.
Eur Urol
. 2023 Jul;
85(5):457-465.
PMID: 37414703
Background: Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed....
9.
Hu M, Wong H, Feng Y, Lloyd P, Smith E, Amend K, et al.
JAMA Pediatr
. 2023 May;
177(7):710-717.
PMID: 37213095
Importance: Active monitoring of health outcomes after COVID-19 vaccination offers early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
10.
Voss E, Shoaibi A, Yin Hui Lai L, Blacketer C, Alshammari T, Makadia R, et al.
EClinicalMedicine
. 2023 Apr;
58:101932.
PMID: 37034358
Background: Adverse events of special interest (AESIs) were pre-specified to be monitored for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with COVID-19. Our aim...